Andreas Klostermann active positions
Companies | Position | Start | End |
---|---|---|---|
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Director/Board Member | - | - |
Chief Tech/Sci/R&D Officer | - | - | |
Founder | - | - | |
The Education Foundation of the Forest Lake Area | Director/Board Member | - | - |
Career history of Andreas Klostermann
Former positions of Andreas Klostermann
Companies | Position | Start | End |
---|---|---|---|
conoGenetix biosciences GmbH
conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Chief Executive Officer | 31/12/2001 | 30/09/2017 |
Founder | 31/12/2001 | 30/09/2017 |
Statistics
International
United States | 3 |
Germany | 2 |
Operational
Director/Board Member | 2 |
Founder | 2 |
Chief Executive Officer | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | Health Technology |
The Education Foundation of the Forest Lake Area | |
conoGenetix biosciences GmbH
conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany. | Health Technology |
- Stock Market
- Insiders
- Andreas Klostermann
- Experience